GRAIL Investors Have Opportunity to Lead Securities Fraud Lawsuit

New York, NY – July 23, 2026 – Rosen Law Firm, a global investor rights law firm, is reminding purchasers of GRAIL, Inc. common stock (NASDAQ: GRAL) of the opportunity to lead a securities fraud class action lawsuit. The lawsuit, which has already been filed, targets investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026. The deadline for investors to apply to the Court to serve as lead plaintiff is August 4, 2026.

The complaint alleges that GRAIL made overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and concealing adverse facts about the state of its NHS-Galleri trial. Specifically, the lawsuit claims that defendants concealed that the trial, as executed within the prescribed three-year follow-up period, was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers. Investors allege that GRAIL repeatedly refused to provide detailed top-line results or other data, potentially hiding trends that suggested a longer timeline or a reduced probability of achieving the desired statistical reduction in advanced-stage cancers.

According to the complaint, when the true details of the trial emerged, investors suffered damages. Rosen Law Firm states that individuals who purchased GRAIL common stock during the class period may be entitled to compensation without payment of any out-of-pocket fees or costs, operating under a contingency fee arrangement.

Investors interested in leading the class action or seeking further information are advised to visit Rosen Law Firm's website or contact the firm directly. No class has yet been certified in the action, and investors not seeking to serve as lead plaintiff are not required to take any action at this time.